Foxtrot™ NC PTCA Gains Regulatory Approval in Malaysia

Kuala Lumpur, Malaysia – Shanghai MicroPort Medical (Group) Co., ("MicroPort®") recently gained the regulatory approval from Malaysia's Medical Device Authority ("MDA") for its in-house developed Foxtrot™ NC PTCA Balloon Catheter ("Foxtrot™ NC").
Foxtrot™ NC is indicated for pre-dilation as well as post-dilation. The shaft has a combination of single lumen and dual lumens tubing and is made from high polymer material with high pressure resistance. Foxtrot™ NC is a low-compliant balloon catheter and has a short deflation time. Super hydrophilic coating allows the catheter to move freely in vessels and reach the narrow lesion area smoothly. Two radiopaque markers aid in the positioning of the balloon under fluoroscopy during procedures. Foxtrot™ NC has excellent crossability, trackability and pushability. Foxtrot™ NC approved in Malaysia has a total of 60 specifications, covering 10 diameters (2.2mm to 5.0mm) and six lengths (6mm, 8mm, 10mm, 12mm, 15mm and 20mm).
Previously, Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") and Foxtrot™ Pro PTCA Balloon Catheter were approved to enter the Malaysia market. As Foxtrot™ NC also gained the regulatory approval, it will further diversify MicroPort®'s cardiovascular product line in Malaysia and offer more comprehensive solutions for local patients. Meanwhile, it is expected to help MicroPort® further consolidate and expand its market share of cardiovascular products in Malaysia and other overseas markets.